JP2005501796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501796A5 JP2005501796A5 JP2002521452A JP2002521452A JP2005501796A5 JP 2005501796 A5 JP2005501796 A5 JP 2005501796A5 JP 2002521452 A JP2002521452 A JP 2002521452A JP 2002521452 A JP2002521452 A JP 2002521452A JP 2005501796 A5 JP2005501796 A5 JP 2005501796A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- quinazolin
- methoxy
- phenyl
- biperazinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-indolyloxy, 5-indolyloxy Chemical group 0.000 description 20
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 18
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 8
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000005978 1-naphthyloxy group Chemical group 0.000 description 1
- RYWKDIFSHGFLKN-UHFFFAOYSA-N 4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]-n-(4-naphthalen-1-yloxyphenyl)piperazine-1-carboxamide Chemical compound C1=CC=C2C(OC3=CC=C(C=C3)NC(=O)N3CCN(CC3)C=3N=CN=C4C=C(C(=CC4=3)OC)OCCOC)=CC=CC2=C1 RYWKDIFSHGFLKN-UHFFFAOYSA-N 0.000 description 1
- YNQJCOMRDQJVNA-UHFFFAOYSA-N 4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]-n-(4-naphthalen-2-yloxyphenyl)piperazine-1-carboxamide Chemical compound C1=CC=CC2=CC(OC3=CC=C(C=C3)NC(=O)N3CCN(CC3)C=3N=CN=C4C=C(C(=CC4=3)OC)OCCOC)=CC=C21 YNQJCOMRDQJVNA-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- RRSQVEJCLLAEAT-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1NC(N(CC1)CCN1c1ncnc(C=C2OCCCN3CCC(C)CC3)c1CC2(C)OC)=O Chemical compound CC(C)Oc(cc1)ccc1NC(N(CC1)CCN1c1ncnc(C=C2OCCCN3CCC(C)CC3)c1CC2(C)OC)=O RRSQVEJCLLAEAT-UHFFFAOYSA-N 0.000 description 1
- ZRCLLIDFMWBFFK-UHFFFAOYSA-N COc1cc2c(N(CC3)CCN3C(Nc(cc3)ccc3C#N)=O)ncnc2cc1OCCCN1CCOCC1 Chemical compound COc1cc2c(N(CC3)CCN3C(Nc(cc3)ccc3C#N)=O)ncnc2cc1OCCCN1CCOCC1 ZRCLLIDFMWBFFK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FLWVPBCUGYXRMY-UHFFFAOYSA-N n-(4-cyanophenyl)-4-[6-methoxy-7-[2-(2h-tetrazol-5-yl)ethoxy]quinazolin-4-yl]piperazine-1-carboxamide Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(=CC=3)C#N)N=CN=C2C=C1OCCC1=NN=NN1 FLWVPBCUGYXRMY-UHFFFAOYSA-N 0.000 description 1
- IIHNRXKTMNLPSH-UHFFFAOYSA-N n-[4-(1h-indol-4-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazine-1-carboxamide Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=NC=1N(CC1)CCN1C(=O)NC(C=C1)=CC=C1OC1=CC=CC2=C1C=CN2 IIHNRXKTMNLPSH-UHFFFAOYSA-N 0.000 description 1
- JDPYFIGKIIQSSF-UHFFFAOYSA-N n-[4-(1h-indol-5-yloxy)phenyl]-4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazine-1-carboxamide Chemical compound C1=C2NC=CC2=CC(OC2=CC=C(C=C2)NC(=O)N2CCN(CC2)C=2N=CN=C3C=C(C(=CC3=2)OC)OCCOC)=C1 JDPYFIGKIIQSSF-UHFFFAOYSA-N 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22612200P | 2000-08-18 | 2000-08-18 | |
| US60/226,122 | 2000-08-18 | ||
| PCT/US2001/041752 WO2002016351A1 (en) | 2000-08-18 | 2001-08-17 | Quinazoline derivatives as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005501796A JP2005501796A (ja) | 2005-01-20 |
| JP2005501796A5 true JP2005501796A5 (https=) | 2008-10-30 |
| JP5073147B2 JP5073147B2 (ja) | 2012-11-14 |
Family
ID=22847639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002521452A Expired - Fee Related JP5073147B2 (ja) | 2000-08-18 | 2001-08-17 | キナーゼインヒビターとしてのキナゾリン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US6982266B2 (https=) |
| EP (3) | EP1315715B1 (https=) |
| JP (1) | JP5073147B2 (https=) |
| KR (1) | KR100831116B1 (https=) |
| CN (1) | CN100358890C (https=) |
| AT (1) | ATE402169T1 (https=) |
| AU (1) | AU8544901A (https=) |
| BR (1) | BR0113356A (https=) |
| CA (1) | CA2426440C (https=) |
| CY (1) | CY1110460T1 (https=) |
| CZ (1) | CZ304061B6 (https=) |
| DE (1) | DE60134990D1 (https=) |
| DK (1) | DK1315715T3 (https=) |
| EA (1) | EA005809B1 (https=) |
| ES (1) | ES2311023T3 (https=) |
| HU (1) | HU228668B1 (https=) |
| IL (2) | IL154514A0 (https=) |
| MX (1) | MXPA03001359A (https=) |
| NO (1) | NO323782B1 (https=) |
| NZ (1) | NZ524461A (https=) |
| PT (1) | PT1315715E (https=) |
| SI (1) | SI1315715T1 (https=) |
| WO (1) | WO2002016351A1 (https=) |
| ZA (1) | ZA200301510B (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2354039T3 (es) | 2000-08-18 | 2011-03-09 | Millennium Pharmaceuticals, Inc. | Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr. |
| WO2002016361A2 (en) | 2000-08-18 | 2002-02-28 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
| AU8544901A (en) * | 2000-08-18 | 2002-03-04 | Cor Therapeutics Inc | Quinazoline derivatives as kinase inhibitors |
| DE60144284D1 (de) * | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| EP1490362A2 (en) | 2001-03-08 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| ATE302771T1 (de) | 2001-12-27 | 2005-09-15 | Theravance Inc | Indolinon-derivative als protein-kinasehemmer |
| AU2003256922A1 (en) * | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
| JP4588447B2 (ja) | 2002-08-09 | 2010-12-01 | セラヴァンス， インコーポレーテッド | 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法 |
| ES2290529T3 (es) * | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
| JP2008504292A (ja) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 免疫増強用の化合物 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US20090029982A1 (en) * | 2005-04-28 | 2009-01-29 | Supergen, Inc. | Protein kinase inhibitors |
| JP2009502804A (ja) * | 2005-07-20 | 2009-01-29 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの新規な結晶形 |
| WO2007100880A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US8198266B2 (en) | 2006-10-31 | 2012-06-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of an EGFR antagonist for the treatment of glomerolonephritis |
| JP5250901B2 (ja) * | 2007-02-23 | 2013-07-31 | 学校法人慶應義塾 | アニリノキナゾリン系化合物及びその用途 |
| EP2139869A2 (en) * | 2007-04-13 | 2010-01-06 | SuperGen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
| EP2370417A2 (en) * | 2008-11-21 | 2011-10-05 | Millennium Pharmaceuticals, Inc. | Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| CN102942529B (zh) * | 2012-11-09 | 2015-06-24 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| CN103288760B (zh) * | 2013-05-16 | 2015-02-18 | 苏州明锐医药科技有限公司 | 卡奈替尼的制备方法 |
| WO2015009889A1 (en) | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| CN112533602A (zh) | 2018-04-05 | 2021-03-19 | 大日本住友制药肿瘤公司 | Axl激酶抑制剂及其用途 |
| CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
| MX2021000887A (es) | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| CN115108999B (zh) * | 2019-07-26 | 2023-11-03 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
| CN111773440B (zh) * | 2020-05-22 | 2026-04-17 | 南京大学 | 一种基于类酶催化反应的抗凝血材料 |
| CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| NZ330571A (en) * | 1996-10-01 | 1999-10-28 | Kyowa Hakko Kogyo Kk | Nitrogenous heterocyclic compounds that may contain sulphur or oxygen |
| DE69943144D1 (de) * | 1998-03-31 | 2011-03-03 | Kyowa Hakko Kirin Co Ltd | Stickstoffenthaltende heterocyclische verbindungen |
| EP1309567A2 (en) | 2000-08-18 | 2003-05-14 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic compounds |
| ES2354039T3 (es) | 2000-08-18 | 2011-03-09 | Millennium Pharmaceuticals, Inc. | Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr. |
| WO2002016361A2 (en) | 2000-08-18 | 2002-02-28 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
| AU8544901A (en) * | 2000-08-18 | 2002-03-04 | Cor Therapeutics Inc | Quinazoline derivatives as kinase inhibitors |
| EP1490362A2 (en) | 2001-03-08 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| WO2003000188A2 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| US7456189B2 (en) * | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
-
2001
- 2001-08-17 AU AU8544901A patent/AU8544901A/xx active Pending
- 2001-08-17 AT AT01964612T patent/ATE402169T1/de active
- 2001-08-17 CN CNB018173527A patent/CN100358890C/zh not_active Expired - Fee Related
- 2001-08-17 JP JP2002521452A patent/JP5073147B2/ja not_active Expired - Fee Related
- 2001-08-17 ES ES01964612T patent/ES2311023T3/es not_active Expired - Lifetime
- 2001-08-17 EP EP01964612A patent/EP1315715B1/en not_active Expired - Lifetime
- 2001-08-17 US US10/344,736 patent/US6982266B2/en not_active Expired - Fee Related
- 2001-08-17 IL IL15451401A patent/IL154514A0/xx active IP Right Grant
- 2001-08-17 BR BR0113356-0A patent/BR0113356A/pt active Search and Examination
- 2001-08-17 KR KR1020037002381A patent/KR100831116B1/ko not_active Expired - Fee Related
- 2001-08-17 MX MXPA03001359A patent/MXPA03001359A/es active IP Right Grant
- 2001-08-17 EA EA200300265A patent/EA005809B1/ru not_active IP Right Cessation
- 2001-08-17 EP EP10182322A patent/EP2277877A1/en not_active Withdrawn
- 2001-08-17 CA CA2426440A patent/CA2426440C/en not_active Expired - Fee Related
- 2001-08-17 NZ NZ52446101A patent/NZ524461A/xx not_active IP Right Cessation
- 2001-08-17 SI SI200130872T patent/SI1315715T1/sl unknown
- 2001-08-17 HU HU0302615A patent/HU228668B1/hu not_active IP Right Cessation
- 2001-08-17 DK DK01964612T patent/DK1315715T3/da active
- 2001-08-17 PT PT01964612T patent/PT1315715E/pt unknown
- 2001-08-17 EP EP08075237A patent/EP1964839A3/en not_active Ceased
- 2001-08-17 DE DE60134990T patent/DE60134990D1/de not_active Expired - Lifetime
- 2001-08-17 WO PCT/US2001/041752 patent/WO2002016351A1/en not_active Ceased
- 2001-08-17 CZ CZ20030765A patent/CZ304061B6/cs not_active IP Right Cessation
-
2003
- 2003-02-17 NO NO20030747A patent/NO323782B1/no not_active IP Right Cessation
- 2003-02-18 IL IL154514A patent/IL154514A/en not_active IP Right Cessation
- 2003-02-26 ZA ZA200301510A patent/ZA200301510B/en unknown
-
2005
- 2005-08-22 US US11/210,028 patent/US7560461B2/en not_active Expired - Fee Related
-
2008
- 2008-10-21 CY CY20081101177T patent/CY1110460T1/el unknown
-
2009
- 2009-05-22 US US12/471,280 patent/US8324205B2/en not_active Expired - Fee Related
-
2012
- 2012-11-02 US US13/667,489 patent/US20130274252A1/en not_active Abandoned
-
2014
- 2014-07-09 US US14/327,312 patent/US20150133439A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501796A5 (https=) | ||
| CA2426440A1 (en) | Quinazoline derivatives as kinase inhibitors | |
| RU2264389C2 (ru) | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения | |
| JP2009537546A5 (https=) | ||
| CA2396590A1 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| RU2002121645A (ru) | Производные 2-аминоникотинамида и их применение в качестве ингибиторов vegf-рецептора тирозинкиназы | |
| RU2008149948A (ru) | Противоопухолевое средство против рака щитовидной железы | |
| RU2003114740A (ru) | Азотсодержащие ароматические производные | |
| JP2008515913A5 (https=) | ||
| JP2004517049A5 (https=) | ||
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| RU2002122095A (ru) | Новое пипиридиновое соединение и его фармацевтическая композиция | |
| JP2008517945A5 (https=) | ||
| RU95118133A (ru) | Гетероциклические соединения, способы их получения и фармацевтическая композиция | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2003507342A5 (https=) | ||
| JP2012510989A5 (https=) | ||
| JP2004508357A5 (https=) | ||
| JPH10279578A5 (https=) | ||
| JP2008515913A (ja) | 多発性嚢胞腎の治療のための方法 | |
| JP2005508923A5 (https=) | ||
| RU2009126633A (ru) | Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений | |
| RU2002111866A (ru) | Производные N-замещенного индол-3-глиоксиламида - противоопухолевое лекарственное средство и средство, подавляющее ангиогенез (варианты), фармацевтическая композиция и противоопухолевое лекарственное средство (варианты) |